AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel, is launching a Phase I/II study titled ‘A Master Protocol Phase I/II Study to Investigate Biomarker-Guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy for the Treatment of Participants With Advanced/Recurrent Ovarian Cancer.’ The study aims to assess the safety, tolerability, and preliminary efficacy of new anticancer agents guided by biomarkers, specifically targeting advanced or recurrent ovarian cancer.
The intervention being tested is Saruparib, an experimental drug administered orally. It is designed to treat patients with BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer, either as a standalone therapy or in combination with other treatments.
This open-label, multicenter study employs a non-randomized, single-group assignment model with no masking, focusing primarily on treatment. The study will include multiple parallel substudies under a master protocol, with Substudy 1 focusing on Saruparib monotherapy.
The study is set to begin on July 31, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on July 10, 2025, indicating the study is not yet recruiting.
The initiation of this study could influence AstraZeneca’s stock performance positively, as successful outcomes may enhance the company’s oncology portfolio. Investors should watch for developments, especially considering the competitive landscape in cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.